Capsida reports progress after gene therapy trial death (single-sourced: STAT). Following the death of a patient in its gene therapy trial for a brain disease, Capsida has reported progress in the follow-up investigation, STAT reported on Tuesday. The update is the company’s first substantive word on the path forward for the program since the death was disclosed.
Helus psychedelic improves depression, with safety questions (single-sourced: STAT). A psychedelic drug from Helus improved depression in a clinical study, STAT reported, while leaving safety questions that will shape the program’s next steps. The readout adds to a crowded field of psychedelic mental health programs working toward pivotal trials.
Flagship launches UK lab venture (single-sourced: Endpoints News). Flagship Pioneering has launched a UK laboratory to build AI-driven biotechnology companies, backed by a 100 million pound investment, Endpoints News reported. The venture extends the Flagship company-creation model, behind Moderna, into the United Kingdom’s life sciences cluster.